Pharma Company Selects OmniComm Platform
Fort Lauderdale, FL. - OmniComm Systems, Inc., a global leading provider of clinical data management technology, today announced that a global top 15 pharmaceutical organization selected TrialOne to automate its entire Phase I and BA/ BE clinic. The expressed aims are to standardize processes, improve business intelligence, ensure compliance, and achieve overall business transformation within its early phase research. TrialOne is a browser-based bedside data collection technology specifically designed to automate the workflows and processes within early phase research clinics. TrialOne is the market leading eSource system for early phase research clinics that addresses the following needs of this pharmaceutical organization:
- Manage and optimize patient screening and recruitment
- Fully validated eSource from paper source records
- Implement data capture from subject bedside
- Automated data capture from medical monitoring equipment and devices
- Streamline staff training and support records
- Integration with laboratory information management systems (LIMS) for lab orders and lab results processing
TrialOne enables the automation of clinic data collection; standardizes recruiting; facilitates the collection of study data and sample tracking; reduces discrepancies inherent in paper-based applications; and ensures compliance. “With this key additional TrialOne success, OmniComm continues to reinforce its position as the market leader in early phase clinic automation,” said Kuno van der Post, SVP of business development, OmniComm Systems. “The close interaction with our major pharmaceutical and clinical research organization (CRO) clients has driven our solution to the point that one of the key reasons we were selected was in no small part due to references from our installed user base.”
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,800 clinical trials. For more information, visit
www.omnicomm.com
.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
